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Renal cell carcinoma as a cause of end-stage renal disease in The incidence of renal cell carcinoma (RCC) in end-
the United States: Patient characteristics and survival. stage renal disease (ESRD) patients after the onset of
Background. The patient characteristics and mortality asso-
dialysis in the United States is significantly more com-ciated with renal cell carcinoma (RCC) as a cause of end-
mon than in the general population [1] and has increasedstage renal disease (ESRD) have not been characterized for
a national population. significantly in recent years in both the ESRD population
Methods. An historical cohort study of renal cell carcinoma [1] and the general population [2]. The prevalence of
(RCC) was conducted from April 1, 1995, to December 31,
RCC in ESRD patients at the time of renal transplanta-1999. Included were 360,651 patients in the United States Renal
tion has most consistently been reported as 0.6% [3–7].Data System (USRDS) who were initiated on ESRD therapy
with valid causes of ESRD. Untreated, RCC uncommonly causes renal failure [8].
Results. Of the study population, 1646 patients (0.5%) had Progressive renal failure has been noted even after par-
RCC. The mean age of patients with RCC was 66.8  14.6
tial nephrectomy; in fact, RCC patients are at greateryears versus 61.3  16.4 years for patients with other causes
risk of chronic renal failure after partial nephrectomyof ESRD (P  0.01 by Student t test). The unadjusted 3-year
survival (censored at the date of renal transplantation) of pa- than a similar cohort of patients who underwent partial
tients with RCC during the study period was 23% versus 36% nephrectomy for other reasons [9].
in all other patients [adjusted hazard ratio (AHR), 1.10, 95%
Nephrectomy is generally performed for nonmeta-confidence interval (CI) 1.02–1.19, P  0.019 by Cox regres-
static disease [10]. Early reports recommend a minimumsion]. However, patients with RCC who underwent nephrec-
tomy (bilateral or unilateral) had significantly better survival waiting time of 12 months prior to renal transplantation
compared to RCC patients who did not (AHR, 0.73, 95% CI, because of the possibility of disease recurrence [11–13],
0.63–0.85, P  0.01), and their survival was not significantly
which has since increased to 24 months. [14] Exceptionsdifferent in comparison with nondiabetic ESRD patients. Bilat-
are sometimes made for patients with localized diseaseeral nephrectomy (vs. unilateral) was not associated with any
difference in adjusted mortality. associated with acquired renal cystic disease, which is
Conclusion. Among patients with ESRD, the demographics usually low grade. The recurrence rate for RCC after
of those with RCC were similar to those of patients with RCC
renal transplantation was 21%, and was not affected byin the general population. Overall, patients with RCC had
waiting time on dialysis (abstract; Buell JF et al: Am Jdecreased survival compared to patients with other causes of
ESRD; those who underwent nephrectomy had significantly Transplant 2:461, 2002) However, survival for patients
better survival than those who did not, with survival compara- with ESRD due to RCC has not been compared with that
ble to patients with nondiabetic ESRD.
of other patients with ESRD, particularly nondiabetic
ESRD, in a national population. Given the lower rate of
The opinions are solely those of the authors and do not represent an renal transplantation for such patients due to mandatory
endorsement by the Department of Defense or the National Institutes
waiting times, such information would be useful for pa-of Health. This is a U.S. government work. There are no restrictions
on its use. tients and clinicians alike. Therefore, we conducted an
historical cohort study of the United States Renal DataKey words: renal cell carcinoma, nephrectomy, Caucasian, male, trans-
System (USRDS). Our objectives were to determine fac-plantation, complications, dialysis, USRDS, age.
tors associated with RCC as causes of ESRD, and deter-
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METHODS tions) and Student t test (Mann-Whitney for non-normal
distributions) for continuous variables. Variables withThe USRDS was analyzed in an historical cohort study
P  0.10 in univariate analysis for a relationship withof the rate, risk factors, and mortality associated with
ESRD due to renal cell carcinoma, including race, age,ESRD due to renal cell carcinoma in ESRD patients.
gender, year of first dialysis session, and additional vari-The variables included in the USRDS standard analysis
ables from the medical evidence form (Table 1), werefiles (SAFs), as well as data collection methods and vali-
entered into multivariate analysis as covariates. An ex-dation studies, are listed at the USRDS web site, under
ception was made for factors thought to have a biologicResearcher’s Guide to the USRDS Database, Section
relationship with RCC [16].E, Contents of all the SAFs (Standard Analysis Files),
Step-wise logistic regression models were performedand published in the USRDS (www.usrds.org). The de-
to test associations with ESRD due to renal cell carci-mographics of the dialysis population have been pre-
noma, using covariates as specified above. No valuesviously described (2002 USRDS report). The files SAF.-
were censored in this analysis. Patient survival curvesPATIENTS were used as the primary data set, including
were calculated using Kaplan-Meier analysis with pa-cause of renal disease (PDIS) and cause and date of
tients censored at time of loss to follow-up. Survival waspatient death. SAF.MEDEVID was used for additional
calculated from 90 days after the date of the first dialysisinformation coded in the medical evidence form starting
session until death, last follow-up visit, or loss to follow-in 1995 and has been validated for use in research [15].
up occurring 90 days after the first dialysis session forTherefore, patients who presented with ESRD on or
patients who were not eligible for Medicare at the startafter April 1, 1995, and through December 31, 1999,
of dialysis, and immediately after the onset of dialysiswere selected for the study and followed through April
in patients who were eligible for Medicare at the time2000. In order to identify patients with RCC, we used
of initiation of dialysis. Covariates were as for univariatecauses of renal failure due to renal cell carcinoma (codes
analysis. Because most hospitalized nephrectomies oc-1890B, 1890Z, 1891Z, 1899A, or 189Z, excluding renal
curred close to the time of the first dialysis treatment,
lymphoma).
nephrectomy was not analyzed as a time-dependent vari-
In order to assess possible associations between ne-
able. However, an additional variable for nephrectomies
phrectomy and patient survival in this cohort, hospital-
performed within 5 months before or within 5 months
izations for nephrectomy were extracted from the file
after the first dialysis date was also analyzed. Step-wise
SAF.HOSP and merged with the main file using unique Cox regression analysis was also performed for survival
patient identifiers. Nephrectomy was determined from analysis, adjusting for age, race, gender, year of first
ICD9 procedure codes (55.4 for partial nephrectomy, dialysis, and comorbidities in the Medical Evidence
55.5 for complete nephrectomy, and 55.54 for bilateral Form (2728). Only variables significantly associated with
nephrectomy). However, the date ranges available for renal cell carcinoma in logistic regression analysis were
hospitalized nephrectomy were limited to hospitaliza- entered as covariates in survival analysis (Table 1). Log-
tions occurring more than 90 days after the start of dial- log plots were used to assess the validity of the propor-
ysis for patients who were not Medicare eligible at the tional hazards assumption over time.
time of dialysis initiation, until December 31, 1999 (the
most recent date for hospitalizations available from the
RESULTSUSRDS). For patients who were Medicare eligible prior
to the initiation of dialysis, information on hospitaliza- Characteristics of the study population are shown in
tions for nephrectomy prior to the first date of treatment Table 1. Mean follow-up was 2.12  1.15 years. Of the
for end- stage renal disease was available for an undeter- study population, 1646 (0.5%) had RCC. The mean age
mined proportion of patients. Because of the potential of patients with RCC was 66.8 14.6 years versus 61.3
impact of age and Medicare eligibility on hospitalization 16.4 years for patients with other causes of ESRD (P 
reporting for nephrectomy, stratified analyses were also 0.01 by Student t test). Of patients with RCC, 64% were
performed for patients aged 65 and older and those who aged 65 or older versus 48% of patients with ESRD due
were eligible for Medicare at the time of their first ESRD to other causes (P  0.01 by chi-square). In logistic
session. regression (far right column, Table 1), patients with RCC
All analyses were performed using SPSS 11.5 (SPSS, compared to patients with other causes of ESRD were
Inc., Chicago, IL, USA). Files were merged and con- significantly more likely to be men, Caucasian, older, on
verted to SPSS files using DBMS/Copy (Conceptual hemodialysis (compared with peritoneal dialysis), have
Software, Houston, TX, USA). Statistical significance higher body mass index (BMI), and less likely to have
was defined as P  0.05. Univariate analysis was per- significant comorbidities except for cancer, receive predi-
formed with chi-square testing for categorical variables alysis erythropoietin (EPO), and be listed for, or receive,
renal transplantation. There was no significant difference(Fisher exact test for violations of Cochran’s assump-
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Table 1. Factors assessed in U.S. chronic dialysis patients from April 1–31, 1995, to December 1999
Univariate odds Adjusted odds ratio for
Factor N  375,857 Missing, N % ratio for RCC RCC in logistic regression
N with valid causes of ESRD 360,651
Mean follow-up years 2.121.15
Male recipient (female) 199,536 (53.1) 0 2.51 (2.25–2.80) 2.03 (1.76–2.35)
African American (vs. other races) 109,791 (29.2) 0 0.48 (0.42–0.55) 0.66 (0.55–0.78)
Year of first dialysis (per more recent year) 1996.91.3 0
Mean age years 61.116.5 0 1.02 (1.01–1.03) 1.02 (1.01–1.03)
Predialysis EPO yes/no 89,611 (24.9) 16,106 (4.5) 0.66 (0.58–0.75) 0.75 (0.64–0.88)
Cause of ESRD vs. all other causes
Diabetes 157,726 (43.7) 15,216 (4.4) ND ND
PKD 8681 (2.4) 15,216 (4.4) ND ND
Data from CMS form 2728
Weight kg 71.816.8 13,450 (3.7)
Body mass index kg/m2 25.25.1 16,341 (4.5) 0.98 (0.97–0.99) 1.04 (1.02–1.05)
Serum creatinine mg/dL 8.03.7 4277 (1.2) 1.00 (0.99–1.02)b 0.97 (0.95–0.99)
Hematocrit % 26.98.5 599 (0.2) 1.00 (0.99–1.01)b 1.03 (1.02–1.04)
History of diabetes primary (as a comorbidity) yes/no 141,983 (39.5) 16,106 (4.5) 0.18 (0.15–0.21) 0.27 (0.23–0.32)
History of diabetes, insulin requiring yes/no 84,006 (23.4) 16,106 (4.5) 0.14 (0.10–0.18) 0.29 (0.22–0.37)
History of hypertension yes/no 261,669 (72.7) 16,106 (4.5) 0.36 (0.33–0.39) 0.43 (0.39–0.48)
History of ischemic heart disease yes/no 83,932 (23.3) 16,106 (4.5) 0.63 (0.55–0.71) 0.78 (0.65–0.94)
History of stroke yes/no 32,440 (9.0) 16,106 (4.5) 0.50 (0.40–0.63) 0.61 (0.46–0.81)
History of congestive heart failure yes/no 116,524 (32.4) 16,106 (4.5) 0.47 (0.41–0.53) 0.66 (0.56–0.78)
History of alcoholism yes/no 5781 (1.5) 16,106 (4.5) 0.70 (0.44–1.10)a 0.52 (0.29–0.54)
History of cancer yes/no 18,101 (5.0) 16,106 (4.5) 32.5 (29.5–35.9) 18.41 (16.13–21.02)
Hemodialysis (vs. peritoneal dialysis) 314,687 (87.4) 15,931 (4.4) 2.28 (2.26–3.52) 1.57 (1.18–2.08)
Receipt of renal transplant yes/no 25,907 (6.9) NA 0.26 (0.18–0.38) 0.56 (0.34–0.93)
Hospitalization for nephrectomy yes/no 3989 (1.1) NA 32.4 (18.8–36.4) 14.50 (12.60–20.66)
Hospitalization for bilateral nephrectomy yes/no 427 (0.1) NA 8.9 (5.4–14.6) 7.28 (4.37–12.13)
Abbreviations are: ESRD, end-stage renal disease renal disease; EPO, erythropoietin; RCC, renal cell carcinoma; PKD, polycystic kidney disease.
Data are given as the number (% of total) or mean  standard deviation. Adjusted odds ratios (by logistic regression) of the strength of association with RCC
as a cause of end-stage renal disease are shown in the far right column. Variables used in logistic regression analysis are specified in the Methods section. ND is not
determined.
a P  0.05 by Chi-square; bP  0.05 by univariate logistic regression
in serum albumin levels between patients with RCC and
other causes of ESRD.
Hospitalization reporting status was affected by Medi-
care eligibility at the time of first ESRD treatment. Of
study patients aged 65 and older, 79.2% were eligible
for Medicare at the time of the first ESRD treatment
compared to 20.8% of patients aged younger than 65.
Of patients with RCC, 24% underwent nephrectomy
compared with 1% of patients with ESRD from other
causes [odds ratio (OR), 32.4, 95% CI, 28.8–36.4, P 
0.01 by chi-square]. The time of nephrectomy relative
to the first date of ESRD treatment is shown for all
patients with RCC (Fig. 1), and for RCC patients who
were not eligible for Medicare (Fig. 2). When limited
to patients aged 65 and older, 33% of RCC patients
underwent nephrectomy, compared to 1.0% of patients
with ESRD due to other causes. Conversely, of 3989 Fig. 1. Time, in months, of nephrectomy in relation to date of first
end-stage renal disease (ESRD) session in all ESRD patients with renalnephrectomies, 10.5% were performed on patients with
cell carcinoma (RCC) who initiated ESRD between April 1, 1995, and
RCC; this number was 16.7% when limited to patients December 31, 1999, and underwent nephrectomy prior to December
31, 1999, who were eligible for Medicare at the time of first ESRDaged 65 and older. The mean age of patients with RCC
service. Percentage of patients aged 65 or older is 88%. N  372.who underwent nephrectomy was 71.6 9.6 years versus
57.9  20.9 years for patients with ESRD from other
causes who underwent nephrectomy (P 0.0001 by Stu- nephrectomy (P 0.01 by Chi-square). Of RCC patients
dent t test). Of RCC patients who underwent nephrec- who did not undergo nephrectomy, 57% were aged 65
tomy, 87% were aged 65 and older compared to 51% of and older compared with 48% of patients with ESRD
due to other causes who did not undergo nephrectomypatients with ESRD due to other causes who underwent
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ment, is shown in Figures 1 and 2. Figure 1 shows the
time to nephrectomy for patients with ESRD due to
RCC who were eligible for Medicare at the time of their
first ESRD treatment. As shown, most nephrectomies
occurred in the same month as the first ESRD session,
with a small proportion occurring afterward. Of patients
with ESRD due to RCC, 67% of nephrectomies were
performed within a period either 5 months before or 5
months after the date of first dialysis. This percentage
was not different depending on Medicare eligibility (67%
for Medicare eligible patients vs. 65% for non-Medicare
eligible patients). For RCC patients who were not eligi-
ble for Medicare at the time of their first ESRD session
(although most were still aged 65 or older), the distribu-
tion of nephrectomy times was similar (Fig. 2). All 16
bilateral nephrectomies in patients with ESRD due to
RCC were performed within 5 months before or after
date of first ESRD treatment (not shown).
Fig. 2. Time, in months, of nephrectomy in relation to date of first Among all ESRD patients, 4.6% of patients with RCC
end-stage renal disease (ESRD) session for all patients with renal cell
were listed for transplant during the study period com-carcinoma (RCC)-initiated ESRD between April 1, 1995, and Decem-
ber 31, 1999, and underwent nephrectomy prior to December 31, 1999, pared to 14.4% of patients with ESRD from other causes;
who were not Medicare eligible at the time of first ESRD service. 1.8% of patients with RCC were transplanted compared
Percentage of patients aged 65 or older is 79%. N  31.
to 6.4% of patients with ESRD due to other causes (P
0.01 by chi-square for both comparisons). Among all
ESRD patients, 30.1% of patients who underwent ne-
phrectomy were listed for transplantation and 28.2%(P  0.01 by chi-square). The mean age of all patients
who underwent nephrectomy was significantly younger were transplanted, compared to 14.4% and 6.7%, respec-
tively, for patients who did not undergo nephrectomythan for ESRD patients who did not undergo nephrec-
tomy (58.9  20.7 years vs. 61.1  16.5 years, P  0.001 (P  0.001 by chi-square). Of patients with RCC, 3%
of patients who underwent nephrectomy were listed forby Student t test). In contrast, the mean age of RCC
patients who underwent nephrectomy was much higher transplantation compared with 5.1% of patients who did
not undergo nephrectomy (P  0.08 by chi-square).than for RCC patients who did not undergo nephrectomy
(71.6  9.6 vs. 65.3  15.5, P  0.001 by Student t test). Among patients with RCC, 1.0% of patients who under-
went nephrectomy were transplanted versus 2.0% of pa-At the time of hospitalization for nephrectomy, the
primary diagnosis was malignant neoplasm of the kidney tients who did not undergo nephrectomy (P  0.17 by
chi-square).(ICD9 code 189.0) in 34% of cases. The next most com-
mon primary diagnosis was hypertensive renal disease In logistic regression of factors associated with bilat-
eral nephrectomy, autosomal-dominant polycystic kid-with renal failure (ICD9 code 403.91, 8%). However, of
patients with RCC, only 16 (1%) underwent bilateral ney disease had the strongest association with bilateral
nephrectomy of all identified causes of ESRD [adjustednephrectomy compared to 0.1% of other ESRD patients
(OR, 8.85, 95% CI, 5.36–14.63, P  0.01 by chi-square). odds ratio (AOR), 16.91, 95% CI, 13.55–21.12), followed
by RCC (AOR, 13.69, 95% CI, 8.07–23.09).Of 427 bilateral nephrectomies, the most common pri-
mary diagnosis was autosomal-dominant polycystic kid- The unadjusted three-year survival of patients with
RCC during the study period was 23% versus 36% inney disease (ADPKD) (23%), followed by hypertensive
renal disease with renal failure (403.91, 15%) and malig- all other patients [adjusted hazard ratio (AHR), 1.10,
95% CI, 1.02–1.19, P  0.019 by Cox regression] (Fig.nant neoplasm of kidney (7%). For patients under age
65, the most common indication for nephrectomy (unilat- 3). The leading specified cause of death in patients with
RCC was malignancy (33.4%). Of patients with RCC,eral or bilateral) was hypertensive renal disease (14%),
complication of kidney transplant (transplantectomy, code 5.8% died of malignancy compared with 0.4% of other
patients with ESRD. In Cox regression analysis, patients996.81, 13%), and malignant neoplasm (12.2%). Polycystic
kidney disease (PKD) was still the most common indication with RCC had an independently greater risk of cancer-
related death (AHR, 2.13, 95% CI, 1.89–2.40, P for bilateral nephrectomies in patients younger than 65.
Time (in months) from the first date of ESRD treat- 0.0001). Patients with RCC who underwent nephrectomy
had significantly better survivals compared to RCC pa-ment to nephrectomy for patients with RCC, stratified
by Medicare eligibility at the time of first ESRD treat- tients who did not undergo nephrectomy (AHR, 0.73,
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Fig. 4. Mortality of patients with end-stage renal disease (ESRD) due
to renal cell carcinoma (RCC) who underwent nephrectomy (unilateralFig. 3. Mortality of patients with end-stage renal disease (ESRD) due or bilateral) (N  404) vs. all others (N  1287) who initiated ESRDto renal cell carcinoma (RCC) (N  1646) vs. nondiabetic ESRD (non- between April 1, 1995 and December 31, 1999. P  0.01 by log-rankDiab) patients (N  201,279) who initiated ESRD between April 1, test.1995, and December 31, 1999. P  0.01 by log-rank test.
statistically significant [2]. Although the increased risk95% CI, 0.63–0.85, P  0.001) (Figs. 4 and 5). When
for whites persisted in the present analysis after adjustingnephrectomy was defined as nephrectomy occurring
for Medicare coverage, we cannot exclude the possibilitywithin a time period 5 months before to 5 months after
that blacks may have had lower rates of screening priorthe first date of dialysis, the survival advantage was even
to ESRD, leading to a lower rate of diagnosed RCC atmore marked (AHR, 0.64, 95% CI, 0.52–0.80, P 
the time of ESRD. A similar controversy is associated0.0001). Furthermore, patients with RCC who under-
with the diagnosis of renovascular disease as a cause ofwent nephrectomy did not have a significantly different
ESRD. [17] The lower use of EPO and a higher hemato-mortality in comparison with nondiabetic ESRD pa-
crit may be associated with continued EPO productiontients. In direct unadjusted comparison limited to pa-
by nests of renal cell carcinoma, which is associated withtients with ESRD due to RCC, patients who underwent
erythrocytosis in the general population [18–20]. A simi-bilateral nephrectomy had improved survival compared
lar association has previously been reported for PKD, awith all other patients with RCC (P  0.045 by log-rank
condition not significantly associated with carcinoma intest), but not in comparison to those who underwent
comparison to other causes of renal disease [1, 21].unilateral nephrectomy. This difference was not signifi-
The present study found that RCC was independentlycant in Cox regression analysis of survival.
associated with increased mortality in patients on chronic
dialysis, with an important caveat: Patients with RCC
DISCUSSION who underwent nephrectomy (unilateral or bilateral)
had no significant difference in mortality compared toThe present study found that the prevalence of RCC
patients with other causes of ESRD, even excluding pa-as a cause of ESRD in the United States chronic dialysis
tients with ESRD due to diabetes. Furthermore, patientspopulation was 0.5%. This is in close agreement both
with RCC having a history of nephrectomy had a signifi-with prior USRDS reports and Denton et al [3], who
cantly lower mortality compared to patients with RCCreported a prevalence of RCC of 0.6% in dialysis patients
who did not have a history of nephrectomy. However,at the time of renal transplantation. Several demographic
nephrectomy may be a marker, although an imperfectassociations with RCC reported by Denton et al were
one, for resectable or limited disease in patients withalso confirmed, including male gender, more common
RCC [22–27] In fact, nephrectomy is often considereduse of hemodialysis than peritoneal dialysis, higher BMI,
part of the staging process in RCC, and detailed patho-and older age. In addition, we report significant associa-
logic evaluation and radiologic staging may be neededtions between RCC and Caucasian race, reduced use of
prior to further treatment [28–34], certainly before un-predialysis EPO, higher predialysis hematocrit, lower
dertaking the transplant evaluation process. In the gen-rate of renal transplantation, and a generally lower rate
eral population, survival after nephrectomy for renal cellof cardiac comorbidities. In contrast, the rate of renal
carcinomas less than 25 mm in size has been excellentcell carcinoma among blacks is higher than whites in
the general population, although this difference was not [24]. Previous studies of the association between RCC
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follow how changes in parameters such as EPO use or
hematocrit changed after nephrectomy in patients with
RCC. This is relevant because nephrectomy is associated
with an increased early (but not necessarily late) risk of
mortality, as well as potential removal of EPO-producing
tissue that might lead to worsened anemia and all of its
attendant risks [40, 41]. However, our findings for both
the prevalence and risk factors for RCC were similar to
previous studies, suggesting that patients with ESRD
attributed to RCC most likely had RCC, whether or not
it was truly the proximate cause of their renal failure.
Underestimation of patients with RCC was unlikely to
affect risk factor or survival analysis, given the rarity of
RCC [1]. Acquired renal cystic disease is more likely to
occur after the onset of dialysis than before, and thusFig. 5. Mortality of patients with end-stage renal disease (ESRD) due
to renal cell carcinoma (RCC) over the age of 65 (N  996) who was less likely to cause renal failure than more aggressive
underwent nephrectomy (unilateral or bilateral) (N 347) vs. all others forms of RCC [1, 42, 43]. In addition, as noted by Denton
(N  649) who initiated ESRD between April 1, 1995, and December
et al [3], most studies assessing the prevalence of either31, 1999. P  0.01 by log-rank test.
renal cell carcinoma or acquired renal cystic disease in
patients with chronic kidney disease have relied on radio-
logic detection without pathologic confirmation. Impor-
and survival have not dealt with tumor staging and extent tant changes in pathologic and clinical scoring of renal
of disease in a consistent fashion [4–7]; therefore, even cell carcinomas have only recently been reported [44, 45].
among single center studies, comparison of results may Extrarenal manifestations of renal cell carcinoma could
be difficult, given the rarity of this condition. However, not be obtained. In addition, the population-based na-
we would agree with Pope et al [35], who concluded ture of this study minimized issues of selection and center
that renal cell carcinoma does not substantially impact bias as well as type II statistical error. The present study
survival in chronic dialysis patients. Our qualification may therefore complement findings from previous sin-
would be that RCC patients with a history of nephrec- gle-center studies.
tomy, and apparently limited disease, appear to do at
least as well on dialysis as patients with other causes of
CONCLUSIONESRD.
The limitations of the current study are similar to This study of chronic dialysis patients in the national
those of other retrospective studies. The reasons for the population confirms previous associations with RCC and
decision to list RCC as the primary cause of end-stage adds findings of new associations. We found that RCC
renal disease were not available for review. Although patients who underwent nephrectomy had survival on
this variable may underestimate the number of ESRD dialysis comparable to patients with other causes of ESRD,
patients with RCC, previous studies of the USRDS indi- including nondiabetic ESRD.
cate that causes of renal failure are specific, particularly
Reprint requests to Kevin C. Abbott, LTC, MC Nephrology Service,for rare conditions. [36–38] We did not have information
Walter Reed Army Medical Center, Washington, D.C. 20307-5001.
on the histologic type of RCC, although transitional cell E-mail: kevin.abbott@na.amedd.army.mil
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